# Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

> **NCT03471351** · PHASE1 · TERMINATED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 2 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Tenalisib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03471351
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-18
- **Primary completion:** 2019-02-13
- **Final completion:** 2019-02-13
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** At this point, the current study in HL does not fit into clinical development and regulatory strategy.
- **Last updated:** 2019-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03471351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03471351, "Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03471351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*